drugset / Trial / NCT06647277

Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease

NCT06647277

Phase 1 Not yet recruiting 10 enrolled ProgenaBiome
NaSingle-groupOpen-labelSupportive care

Summary

FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.

Timeline

Start
2026-07
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Background Vancomycin Other / unclassified

Indications